Archive for the ‘Treatment’ Category

ECU Researcher Gets Money From NIH to Develop Medication for Lyme

http://www.wnct.com/news/health-news/ecu-researcher-tries-to-find-better-way-to-treat-lyme-disease/1239691985

ECU researcher, MD A. Motableb has obtained  $1.7 million from the National Institutes of Health (NIH) to study borrelia, the causative agent of Lyme Disase in the human body.

The hope is to develop a medication.

The article goes on to state deeply entrenched myths about initial symptoms such as the bullseye rash that do not represent many patients.

For more on Lyme:  https://madisonarealymesupportgroup.com/2016/02/13/lyme-disease-treatment/

Psychological symptoms of Lyme:  https://madisonarealymesupportgroup.com/2015/10/18/psychiatric-lymemsids/

I’m not holding my breath for this hoped for medication.  The first thing that has to be acknowledged by main stream medicine and researchers is this is NOT a one pathogen one drug illness.  Patients are often infected with a plethora of pathogens – some viral, some bacterial, some fungal, even nematodes (worms).  They all take different medications.  https://madisonarealymesupportgroup.com/2017/07/01/one-tick-bite-could-put-you-at-risk-for-at-least-6-different-diseases/  The actual number is 18 and counting.

Besides this crucial fact, these pathogens cause all sorts of havoc within the body including inflammation and an autoimmune response.  Many have mast cell issues, newly developed sensitivities, hormonal imbalances, adrenal issues, and on and on to infinity.

This is the perfect storm and it’s complicated to say the least.

 

 

Category:

Activism, Lyme, research, Treatment

Tick-Borne Disease Working Group Subcommittee Reports – Comments due by June 18

https://www.hhs.gov/ash/advisory-committees/tickbornedisease/reports/index.html

Reports

The Tick-Borne Disease Working Group (Working Group) is required to submit a report on its activities and any recommendations to the HHS Secretary and Congress every two years. The first report is due December 2018.

The six subcommittees of the Working Group prepared reports to inform the Working Group and its 14 voting members. These reports offer insights into gaps, opportunities and potentials actions to be considered by the Working Group for the report to Congress and HHS Secretary. 

Report of the Access to Care Services and Support to Patients Subcommittee

Report of the Disease Vectors, Surveillance, and Prevention Subcommittee

Report of the Other Tick-Borne Diseases and Co-Infections Subcommittee

Report of the Pathogenesis, Transmission and Treatment Subcommittee

Report of the Testing and Diagnostics Subcommittee

Report of the Vaccine and Therapeutics Subcommittee

 

You may make comment either by writing or verbally by June 18th, for the next meeting on June 21st.

Go here for the June 21st meeting.
https://www.hhs.gov/ash/advisorycommittees/tickbornedisease/meetings/index.html

 

 

 

 

Category:

Activism, Lyme, Testing, Ticks, Transmission, Treatment, vaccines

Depression: the Radical Theory Linking it to Inflammation

https://www.nature.com/articles/d41586-018-05261-3

BOOKS AND ARTS 29 MAY 2018

Depression: the radical theory linking it to inflammation

Alison Abbott considers a persuasive case for the link between body and mind.

d41586-018-05261-3_15785092
Collage of coloured sagittal MRI scans of the human brain.
Magnetic resonance imaging scans of the human brain.Credit: Simon Fraser/SPL/Getty

The Inflamed Mind: A Radical New Approach to Depression Edward Bullmore Short (2018)

Depression affects one in four people at some time in their lives. It is often difficult to treat, in part because its causes are still debated. Psychiatrist Edward Bullmore is an ardent proponent of a radical theory now gaining traction: that inflammation in the brain may underlie some instances. His succinct, broad-brush study, The Inflamed Mind, looks at the mounting evidence.

The book outlines a persuasive case for the link between brain inflammation and depression. Bullmore pleads with the medical profession to open its collective mind, and the pharmaceutical industry to open its research budget, to the idea. He provides a current perspective on how the science of psychiatry is slowly emerging from a decades-long torpor. He sees the start of a shift in the Cartesian view that disorders of the body ‘belong’ to physicians, whereas those of the more ‘immaterial’ mind ‘belong’ to psychiatrists. Accepting that some cases of depression result from infections and other inflammation-causing disorders of the body could lead to much-needed new treatments, he argues.

In 1989, during his clinical training at St Bartholomew’s Hospital in London, Bullmore encountered a patient whom he calls Mrs P, who had severe rheumatoid arthritis. She left an indelible impression. He examined her physically and probed her general state of mind. He reported to his senior physician, with a certain pride in his diagnostic skill, that Mrs P was both arthritic and depressed. Replied the experienced rheumatologist dismissively, given her painful, incurable physical condition, “You would be, wouldn’t you?”

Mrs P is a recurring motif, as is the rhetorical question. Bullmore draws on more than two millennia of medical history — from ancient Greek physician Hippocrates to the work of neuroanatomist and 1906 Nobel laureate Santiago Ramón y Cajal — to illustrate his points. At times they seem like intellectual meanderings, but these passages also show how medical science often progresses by means of bold theories that break away from received wisdom.

After his training, Bullmore specialized in psychiatry, and quickly experienced its limitations. He describes his growing awareness of how poorly science has served the field, using the development of selective serotonin reuptake inhibitors (SSRIs) as a prime example.

That long and winding road began with the antibiotic iproniazid. It was discovered through scientific logic: by screening chemicals for their ability to kill Mycobacterium tuberculosis in the test tube and in mice. Iproniazid transformed the treatment of tuberculosis in the 1950s. Patients clawed back from the jaws of death exhibited euphoria — well, you would, wouldn’t you? — and the drug was soon launched as an antidepressant. Soon the theory emerged (based more on supposition than evidence, says Bullmore) that its psychiatric effects were the result of boosting the neurotransmitters adrenaline and noradrenaline. Drug developers began to focus on neurotransmission more broadly.

Prozac (fluoxetine), which boosts serotonin transmission, was launched in the mid-1980s, and many pharmaceutical companies quickly followed with their own SSRIs. It seemed to be the revolution psychiatrists had been waiting for. But it soon emerged that only a modest subset of patients benefited (estimates based on trials vary widely). That is unsurprising in retrospect, with the new appreciation that depression can have many causes. Bullmore holds that the emergence of SSRIs bypassed scientific logic. The serotonin theory, he writes, is as “unsatisfactory as the Freudian theory of unquantifiable libido or the Hippocratic theory of non-existent black bile”. He notes that, after SSRIs failed to live up to the hype, time once again stood still for psychiatry.

Bullmore recalls a teleconference in 2010, when he was working part-time with British pharmaceutical giant GlaxoSmithKline. During the call, the company announced it was pulling out of psychiatry research because no new ideas were emerging. In the following years, almost all of ‘big pharma’ abandoned mental health.

Then a window seemed to open — one that shed a different light on the plight of Mrs P. Some of the textbook certainty that Bullmore had learnt by rote at medical school started to look distinctly uncertain.

In particular, the blood–brain barrier turned out to be less impenetrable than assumed. A range of research showed that proteins in the body could reach the brain. These included inflammatory proteins called cytokines that were churned out in times of infection by immune cells called macrophages. Bullmore pulls together evidence that this echo of inflammation in the brain can be linked to depression. That, he argues, should inspire pharmaceutical companies to return to psychiatry.

It seems unfair that someone struck down by infection should have depression too. Is there a feasible evolutionary explanation? Bullmore hazards that depression would discourage ill individuals from socializing and spreading an infection that might otherwise wipe out a tribe.

Other brain disorders might turn out to be prompted or promoted by inflammation. An exciting link with neurodegenerative diseases, including Alzheimer’s, is also being studied (see Nature 556, 426–428; 2018). But we need to learn from the rollercoaster history of brain research, and keep expectations in check. Beneath his bombastic enthusiasm, Bullmore acknowledges this, too.

Nature 557, 633-634 (2018)

doi: 10.1038/d41586-018-05261-

_________________

**Comment**

Lyme/MSIDS patients are often depressed.  I certainly was.  I found the worse I felt physically, the worse I felt mentally.  My mental state improved on appropriate anti-microbial treatment right along with my physical state.

I wholeheartedly believe the reason we are seeing suicides with Lyme/MSIDS is because patients are being abused at every juncture.  They are not believed and live an isolated existence where they can not speak honestly to those closest to them.  If you find yourself in this situation, please, for your mental health, get to a support group.  Once inside those doors you will be affirmed, believed, and listened to.  Don’t have a support group?  Start one!  With an estimated 1 million to contract Lyme/MSIDS this year (2018) there’s going to be a whole lot more of us!  https://madisonarealymesupportgroup.com/2018/02/24/one-million-predicted-to-get-lyme-in-2018-in-the-u-s/

For some other info linking infections to depression:  https://madisonarealymesupportgroup.com/2017/10/03/treat-the-infection-psychiatric-symptoms-get-better/

https://madisonarealymesupportgroup.com/2017/10/01/panspandas-steroids-autoimmune-disease-lymemsids-the-need-for-medical-collaboration/

https://madisonarealymesupportgroup.com/2015/10/18/psychiatric-lymemsids/

https://madisonarealymesupportgroup.com/2017/01/17/lymemsids-and-psychiatric-illness/

https://madisonarealymesupportgroup.com/2017/10/08/misdiagnosed-how-children-with-treatable-medical-issues-are-mistakenly-labeled-as-mentally-ill/

https://madisonarealymesupportgroup.com/2017/06/30/child-with-lymemsidspans-told-by-doctors-she-made-it-all-up/

https://madisonarealymesupportgroup.com/2018/06/04/ld-diagnosis-took-forever-because-of-mental-health-stigma/

https://madisonarealymesupportgroup.com/2018/04/07/young-woman-with-lyme-takes-her-life/

 

 

 

Category:

Activism, Inflammation, Psychological Aspects, Treatment

Corruption & Human Rights Violations Against Lyme Doctors, Scientists, and Parents Now on United Nations Record

https://www.linkedin.com/pulse/corruption-human-rights-violations-against-lyme-now-luche-thayer/

Corruption and Human Rights Violations Against Lyme Doctors, Scientists and Parents Now on United Nations Record

0Published on June 12, 2018
Jenna Luche-Thayer
consulting Senior Advisor – US Government, United Nations, non-profits, corporate social responsibility programs

The 2018 Report ‘The Situation of the Human Rights Defenders of Lyme and Relapsing Fever Borreliosis Patients’ was submitted to Special Rapporteur Michel Forst and to Special Rapporteur Dr. Dainius Puras of the United Nations in March 2018. This resulted in a meeting between United Nations Human Rights Council Special Rapporteur Forst and medical professionals, scientists, human rights experts and advocates on June 5, 2018 in Geneva, Switzerland.

FOR IMMEDIATE RELEASE – June 12, 2018. The United Nations (UN) Special Rapporteur for Human Rights Defenders, Michel Forst, heard presentations on multiple countries from the all voluntary Ad Hoc Committee for Health Equity in ICD11 Borreliosis Codes, whose global members are dedicated to addressing the borreliosis pandemic.

Jenna Luché-Thayer, Director of the Ad Hoc Committee, gave an overview from the 2018 Report ‘The Situation of the Human Rights Defenders of Lyme and Relapsing Fever Borreliosis Patients’ that was followed by representatives sharing cases from their countries. She started by contrasting scenarios where the public recognition of human rights issues differs. For example, most people recognize the devotion to human rights of the journalist who goes into a war zone to find and share the truth of innocent people brutalized by war crimes and the risks taken by the persons who organize to free children from international sex trafficking. These defenders of human rights can be easily identified because they are working to address situations we all can recognize as horrific.

In contrast, the healthcare systems across the globe are largely recognized as flawed but not intentionally horrendous. However, increasing numbers of scholarly publications have documented how these healthcare systems have become quietly corrupted and this has led to a global healthcare situation wherein “criminal activities have become normalized”, according to Dr. Dainius Pūras, the UN Special Rapporteur on the right to health.

The defenders of Lyme and relapsing fever borreliosis patients include medical professionals, doctors, scientists, patients and advocates fighting for the health human rights of this patient group. The Report shows how many of these defenders are routinely defamed, their freedoms to associate and speak restricted, and their livelihoods are threatened. It also shows how parental rights of parents of severely ill children are routinely violated by State Actors.

According to the October 24, 2017 presentation to the UN General Assembly by Dainius Pūras, “In many countries, health is among the most corrupt sectors; this has significant implications for equality and non-discrimination.”

This second Report by the Ad Hoc Committee supports his findings. It details how financial motivations shared among a faction in a medical society, their associates, State Actors and insurers have contributed to a global situation whereby doctors, scientists and parents are attacked because they defend these patients’ rights to health, bodily integrity and life. It is not uncommon for these defenders’ reputations, livelihoods and finances to be ruined — doctors lose their licenses, scientists lose access to research monies and parental rights are violated when ill children under treatment that meet internationally accepted standards are seized from their homes.

Jenna Luché-Thayer, a human rights expert with 33 years of experience in 42 nations reported how the case definition of Lyme borreliosis (LB) was changed by colluding US State Actors and certain members of the Infectious Disease Society of America (IDSA)’ and that the timing of these changes concurred with the launch of a failed Lyme vaccine, promotion of an unreliable, yet profitable diagnostic test system and the unwillingness of US insurers to cover the chronic or persistent form of the disease as they moved into the ‘managed care’ model.

She noted how the revised LB case definition removed most references to the debilitating symptoms, disabling and potentially fatal complications, persistence and severity of the disease and the unreliable diagnostic technologies. She also noted that contrary to the case definition, over 200 patents — held by IDSA members, State Actors and associates — reflect these serious and life-threatening complications, persistence of the disease and how the infection is often missed by the unreliable serology diagnostic technology.

Luché-Thayer detailed how the current situation of these human rights defenders and this patient group shows violations of articles found in eleven international and/or regional human rights treatises and conventions.

She stated that it appears the corruption started in the early 1990s is reflected in the 2006 IDSA Guidelines that have been promoted globally and also appears to have shaped the World Health Organization’s (WHO) International Classification of Diseases (ICD) codes for the disease.

She stated the Report shows how this corruption appears to be globally organized across institutions such as the Association of Medical Microbiology and Infectious Diseases of Canada, European Union Concerted Action on Lyme Borreliosis (currently defunct) European Society of Clinical Microbiology and Infectious Diseases’ Study Group for Lyme Borreliosis (ESGBOR) and State Actors and is driving unnecessary suffering, death and bankruptcy among this patient group.

The former Senior Advisor to the United Nations and U.S. government asked, “There is universal agreement that prisoners have a right to medical care. Precisely what is the difference between a ‘prisoner of war’ and ‘an eight-year-old boy’ being denied medically necessary antimicrobial care? Seizing the business of a political opposition party leader is prohibited. Precisely what is the difference between ‘seizing the businesses from a political opposition party leader’ and a medical board with members representing one medical society ‘closing down the business of a medical doctor that belongs to a competing medical society’?”

Jim Wilson, President of CanLyme, and Jennifer Kravis, co-founder of LymeHope, lawyer and mother of a daughter with tick borne diseases, testified about the situation in Canada. Only two percent of all Canadian doctors have ever been under investigation by their respective provincial Colleges of Physicians and Surgeons whereas nearly 100 percent of the doctors who diagnose and treat LB clinically have either been harassed by their respective provincial Colleges of Physicians and Surgeons to the point they gave up their medical licenses, or were forced to stop seeing Lyme patients.

Dr. Kenneth Liegner (USA) spoke about how he used to cooperate with the US Centers for Disease Control and Prevention and detected the Lyme infection in the spinal fluid of his patient, Vicki Logan, despite prior antibiotic treatment. Early on, her private health insurer covered extended intravenous antibiotic treatment which improved her condition. Later, when in a nursing home and under Medicaid, her intravenous antibiotic treatment was suspended. While Liegner sought mechanisms for Medicaid reimbursement, Vicki experienced grand mal seizures and was transferred to a local hospital where Liegner did not have privileges. There she was found to have low blood pressure, her condition was not investigated and her family was persuaded to support a ‘do not resuscitate’ order. She subsequently died. An autopsy revealed ongoing neurologic Lyme disease and an acute heart attack that was neither diagnosed nor treated. Her case exemplifies the discrimination persons with Lyme experience.

Special Rapporteur Forst also heard of how many of Liegner’s colleagues were bullied into silence or submission; many of them losing their licenses or going bankrupt because of legal costs to fight the allegations made by insurance companies and supported by certain IDSA members. For example, defender Dr. Joseph Burrascano anticipated his own attacks in his 1993 Senate testimony on the apparent corruption and the unethical obstruction to diagnostics and care experienced by this patient group. Liegner also made a point of saying ‘it was not patients who made these allegations’.

French Professor Christian Perronne is an internationally renowned Infectious and Tropical Diseases specialist with over 300 scientific publications and has played an advisory role to WHO. Perronne told the Special Rapporteur how, following his 2016 presentation on LB at France’s Academy National of Medicine, he was publicly called a “terrorist” by former the President of the Academy, Professor Marc Gentilini.

The Ad Hoc Committee recognizes there are other patient groups and defenders’ experiencing similar human rights violations, and with the increasing corruption found in the health sector globally, these violations are trending across more groups. Emeritus Professor Malcolm Hooper (UK) testified how the defenders of an estimated 15-30 million people with Myalgic Encephalomyelitis diagnosis (also known as ‘chronic fatigue syndrome’) are similarly attacked and discredited. He shared how the guidelines for ME treatment also appear to be riddled with conflicts of interests, fraudulent science and harm patients’ health and obstruct their access to disability payments.

While in Geneva, Dutch social scientist and human rights researcher Huib Kraaijeveld and other Ad Hoc Committee members discussed these matters with officials from the Dutch Ministry of Health and Embassy. Ad Hoc members including Dr. Anne Fierlafijn (Belgium), retired senior engineer Michael Cook (UK), biologist Dr. Barbaros Çetin (Turkey), media expert Torben Thomsen (Denmark), human rights expert Dr. Astrid Stuckelberger (Switzerland), psychiatrist Dr. Ursula Talib (Switzerland), scientist Dr. Mualla McManus (Australia) and advocate Theresa Denham (USA) also met with an array of internationally recognized human rights leaders and advisors, documentary film makers, and a number of persons in the Swiss medical system and UN personnel with personal experience of Lyme.

To note, the WHO’s ICD codes for Lyme borreliosis are still inadequate and outdated. When Ad Hoc member Stuckelberger contacted WHO to set a meeting to discuss the LB codes, she received written communications stating that ‘WHO has no person for Lyme borreliosis’– one of the fastest growing vector borne diseases in the world and officially ranked by the European Union as one of the top public health threats in Europe. These inadequate codes may be why in West Africa many persons misdiagnosed with debilitating drug resistant malaria were eventually found to be suffering from borreliosis infection.

According to Ad Hoc Committee founder Luché-Thayer, “This global all-voluntary organization will continue to document the human rights violations and corruption surrounding this borreliosis pandemic; we are committed to addressing these self-serving, financially-motivated threats to global health.”

………………………………………………………. # # # ………………………………………………………………

Contact: Jenna Luché-Thayer at jennaluche@gmail.com

______________

For Vicki Logan’s story:  https://madisonarealymesupportgroup.com/2017/03/09/remember-vicki-logan/

More on the fraud, corruption, and collusion of the CDC and IDSA:  https://madisonarealymesupportgroup.com/2017/11/15/lyme-patients-file-lawsuit-against-idsa-and-insurers-over-treatment-denials/

https://madisonarealymesupportgroup.com/2017/09/25/speaking-of-fake-science-fifty-seven-million-anti-trust-lawsuit-against-cdc-lyme-tests/

https://madisonarealymesupportgroup.com/2016/11/29/spider-attacks-cdc/

https://madisonarealymesupportgroup.com/2018/04/06/cdcs-troubling-lack-of-research-ethics/

https://madisonarealymesupportgroup.com/2017/10/06/remembering-dr-masters-the-rebel-for-lyme-patients-who-took-on-the-cdc-single-handedly/   Masters went over the charts with a fine tooth comb and found huge CDC errors. Another contentious point was the arbitrary cut off date imposed by the CDC which did not pick up serious late-stage symptoms. Another was the CDC’s rejection of many positive blood tests performed in its own lab, as well as other lab work showing “motile spirochetes” in nearly 5% of lone star nymphs. Long story short, after numerous revisions, Masters could never sign onto the bastardized study. The CDC had purposely tossed out data and manipulated the results.  The CDC essentially tried blackmailing Masters into signing off on the study before they would let him see the final draft. Refusing the bait, he published a letter of objection in the Journal of Infectious Diseases as well as an article of his own in Missouri Medicine which showed Missouri patients met the CDC surveillance definition for LD and growing evidence that lone star ticks were infected with an unidentified spirochete causing identical symptoms of LD in patients. When the CDC study came out they unbelievably attributed the rashes they labeled STARI to an allergy to tick saliva! In the acknowledgment section of the paper where dozens of folks were thanked, they completely omitted the man who made it all possible – Dr. Ed Masters. RIP – we will never forget you.

Another example of how insurance companies hide behind the corrupt CDC guidelines:  https://madisonarealymesupportgroup.com/2018/02/14/another-lyme-patient-denied-health-benefits-files-lawsuit/

Category:

Activism, Lyme, Treatment

Caffeine More Dangerous Than Cannabis

 Approx. 2:30

According to Dr. David Bearman, in 1988 after a two rescheduling hearing, the DEA’s chief administrative law judge recommended rescheduling Cannabis to a schedule II substance.  He also said it was one of the safest therapeutic agents known to man & that it was safer than eating 10 potatoes.

According to two well-known addictionologists, Dr. Jack E. Henningfield (National Institute on Drug Abuse) and Dr. Neal L. Benowitz (University of California at San Francisco), Cannabis is less dangerous than caffeine.  http://druglibrary.org/schaffer/library/basicfax5.htm

 They ranked six psychoactive substances on the following five criteria:
  • Withdrawal — The severity of withdrawal symptoms produced by stopping the use of the drug.
  • Reinforcement — The drug’s tendency to induce users to take it again and again.
  • Tolerance — The user’s need to have ever-increasing doses to get the same effect.
  • Dependence — The difficulty in quitting, or staying off the drug, the number of users who eventually become dependent
  • Intoxication — The degree of intoxication produced by the drug in typical use.
The tables listed below show the rankings given for each of the drugs. Overall, their evaluations for the drugs are very consistent. It is notable that marijuana ranks below caffeine in most addictive criteria, while alcohol and tobacco are near the top of the scale in many areas.

 

The rating scale is from 1 to 6. 1 denotes the drug with the strongest addictive tendencies, while 6 denotes the drug with the least addictive tendencies.

HENNINGFIELD RATINGS

Substance   Withdrawal   Reinforcement   Tolerance   Dependence   Intoxication

Nicotine           3                         4                       2                     1                   5

Heroin             2                          2                       1                     2                  2

Cocaine          4                          1                       4                     3                   3

Alcohol           1                           3                       3                     4                  1

Caffeine          5                          6                       5                     5                  6

Marijuana      6                          5                        6                     6                 4

 

BENOWITZ RATINGS

Substance   Withdrawal   Reinforcement   Tolerance   Dependence   Intoxication

Nicotine             3*                       4                     4                        1                6

Heroin                2                        2                      2                        2               2

Cocaine              3*                      1                      1                        3               3

Alcohol               1                        3                      4                        4               1

Caffeine              4                        5                     3                         5               5

Marijuana          5                        6                     5                        6                4

*equal ratings

A neurobiologist shows the under explored potential of cannabis to address opioid addiction:  https://www.sciencedaily.com/releases/2017/02/170202141322.htm

Excerpt:

For example, previous research shows that cannabinoids have a stronger effect on inflammation-based chronic pain, while opioids are particularly good at relieving acute pain. Problematically, opioids can quickly lead to a deadly addiction.

“If you look at both drugs and where their receptors are, opioids are much more dangerous in part because of the potential for overdose. The opioid receptors are very abundant in the brainstem area that regulates our respiration so they shut down the breathing center if opioid doses are high,” says Dr. Hurd. “Cannabinoids do not do that. They have a much wider window of therapeutic benefit without causing an overdose in adults. However, children have overdosed from consuming edible marijuana so that’s something to consider when making decisions regarding medical use.”

…..Accumulating evidence suggests that cannabinoids could have long-lasting therapeutic effects.

 

You may not be aware that medical cannabis is legal in 28 states and the District of Columbia, yet the DEA classifies cannabis as a Schedule I controlled substance, the same category as heroin, yet there is no toxic or lethal overdose effects of cannabis.  No one has ever died from cannabis.

You may also be surprised to learn the United States Department of Health Services owns a patent on cannabis:  https://patents.google.com/patent/US6630507B1/en.

The Patent covers the use of cannabinoids for treating a wide range of diseases. Yet under U.S. federal law, cannabis is defined as having no medical use. The patent (US6630507) is titled “Cannabinoids as antioxidants and neuroprotectants”. It was awarded to the Department of Health and Human Services (HHS) in October 2003. It was filed in 1999, by a group of scientists from the National Institute of Mental Health (NIMH), also part of the National Institutes of Health.

Even the U.S. government’s own NIH researchers concluded:  “Based on evidence currently available the Schedule 1 classification is not tenable; it is not accurate that cannabis has no medical value, or that information on safety is lacking.”  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358713/

For a video guide on the science of cannabis & opioid information: https://healer.com/cannabis-and-opioids-video-guide-the-science/

If you want to learn more on the medicinal uses of cannabis:

Airing FREE June 20-27, 2018 Register here: http://bit.ly/2sGRiuY The Sacred Plant: Healing Secrets Examined is a groundbreaking 7-part documentary series centered on the most powerful and potent healing plant on earth.

Category:

Activism, Herbs, Inflammation, Marijuana, Pain Management, Psychological Aspects, Treatment